ANTX (AN2 Therapeutics) Tariff Resilience Score: 7/10 (As of Jul. 07, 2026)


ANTX AN2 Therapeutics Inc ANTX
22 GF Score
Price $4.42
! 3 Warning Signs
View Full Analysis

What is AN2 Therapeutics Tariff Resilience Score?

AN2 Therapeutics ANTX -0.23% 22 Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus rates ANTX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,368 Biotechnology companies, AN2 Therapeutics ranks better than 90.35% on this metric.

AN2 Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

AN2 Therapeutics has Pharmaceutical company with limited exposure to tariffs due to industry-specific exemptions. Global supply chain but strong pricing power and strategic partnerships enhance resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes AN2 Therapeutics might have Highly Resilient.

AN2 Therapeutics  (NAS:ANTX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

AN2 Therapeutics Tariff Resilience Score Related Terms

ANTX vs OKUR, KRRO, LENZ: Tariff Resilience Score Comparison

For the Biotechnology subindustry, AN2 Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AN2 Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where AN2 Therapeutics's Tariff Resilience Score falls into.


ANTX
22GF Score
AN2 Therapeutics Inc ANTX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
AN2 Therapeutics (ANTX) has a Tariff Resilience Score of 7 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, AN2 Therapeutics ranks #132 out of 1368 companies in the Biotechnology industry, placing it in the top 9.6%.
Is AN2 Therapeutics' Tariff Resilience Score too high?
AN2 Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. AN2 Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, AN2 Therapeutics ranks #132 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AN2 Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does AN2 Therapeutics' Tariff Resilience Score compare to OKUR and KRRO?
According to the Biotechnology industry distribution chart, AN2 Therapeutics ranks #132 out of 1368 companies for Tariff Resilience Score. This places AN2 Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. AN2 Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AN2 Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AN2 Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AN2 Therapeutics stock overvalued right now?
AN2 Therapeutics (ANTX) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. AN2 Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For AN2 Therapeutics (ANTX), the current Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AN2 Therapeutics Business Description

Address 1300 El Camino Real, Suite 100, Menlo Park, CA, USA, 94025
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
22GF Score

Get the complete analysis for ANTX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.42
Price